A5081730514- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Mental Health Research Topics
- Child and Adolescent Psychosocial and Emotional Development
- Treatment of Major Depression
- Schizophrenia research and treatment
- Mental Health and Psychiatry
- Tryptophan and brain disorders
- Bipolar Disorder and Treatment
- Mental Health Treatment and Access
- Psychosomatic Disorders and Their Treatments
- Electroconvulsive Therapy Studies
- Personality Disorders and Psychopathology
- Psychiatric care and mental health services
- Attention Deficit Hyperactivity Disorder
- Pain Management and Placebo Effect
- Cardiac Health and Mental Health
- Health Systems, Economic Evaluations, Quality of Life
- Functional Brain Connectivity Studies
- Family Support in Illness
- Parkinson's Disease Mechanisms and Treatments
- Child Nutrition and Feeding Issues
- Alcohol Consumption and Health Effects
- Receptor Mechanisms and Signaling
- Heart Rate Variability and Autonomic Control
- Child Abuse and Trauma
Lundbeck (Denmark)
2021-2022
International Drug Development
2003
Honeywell (France)
2001
IQVIA (France)
2000
Johannes Gutenberg University Mainz
1985-1995
Roche (Switzerland)
1994-1995
Klinik und Poliklinik für Psychiatrie und Psychotherapie
1988
Max Planck Institute of Psychiatry
1988
University of Mannheim
1988
Background This study investigates the naturalistic course of panic disorder over four years and attempts to identify predictors for outcome. Method 423 DSM–III–R patients who had taken part in an international multicentre drug trial were selected follow-up; we able re-interview 367 (87%). For attacks, phobic avoidance disabilities same rating scales administered as been used clinical trials. Results While 61 % all experienced at least occasional attacks follow-up, few suffered from serious...
ABSTRACT One of the core problems in clinical research is detection early changes target symptoms that predict future therapeutic outcome. To analyze potential predictors outcome, data a multicenter study on patients with panic disorder were used. A total 1010 randomly allocated either to alprazolam, imipramine or placebo treatment. Early improvement number spontaneous attacks within first week treatment predicted outcome exclusively alprazolam group. In contrast, responders and...
Paroxetine and sertraline are the only FDA approved drugs for treatment of posttraumatic stress disorder (PTSD). Although both show better outcomes than placebo, not all patients benefit from treatment. We examined predictors latent classes SSRI response in with PTSD. Symptom severity was measured over a 12-week period 390 suffering PTSD treated open-label or paroxetine double-blinded placebo. First, growth curve modeling (GCM) used to examine population-level response. Second, mixture (GMM)...
Abstract A better understanding of the biological factors underlying antidepressant treatment in patients with major depressive disorder (MDD) is needed. We perform gene expression analyses and explore sources variability peripheral blood related to response suffering from recurrent MDD at baseline after 8 weeks treatment. The study includes 281 patients, which were randomized vortioxetine ( N = 184) or placebo 97). To our knowledge, this largest dataset including both placebo-controlled...
Summary: Classical irreversible monoamine oxidase (MAO) inhibitors are efficacious in anxiety disorders. However, their side-effect profile and the risk for a potentially fatal hypertensive crisis caused by interactions with dietary tyramine limit use. New, reversible of A (RIMAs), such as moclobemide brofaromine, show less potentiation can be taken only minimal restriction. Their broad spectrum antidepressant activity better tolerability than tricyclic antidepressants indicate potential...
ABSTRACT The assessment of endogenous depression by means the Newcastle Scales (1965, 1971) has been validated their correlation with biological findings in many previous studies. However, reliability and cross validation studies are lacking for these scales. We found to be sufficient or at least moderate a sample 70 inpatients major depression. In order validate both scales, clinical classification according ICD‐9 have performed independently 112 Major Depressive Disorder (RDC). rate...